Standout Papers

Analysis of Tumor Specimens at the Tim... 1994 2026 2004 2015 1.9k
  1. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers (2013)
    Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research
  2. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks (2001)
    Javed Khan, Jun S. Wei et al. Nature Medicine
  3. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005)
    William Pao, Gregory J. Riely et al. PLoS Medicine
  4. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2013)
    Neal I. Lindeman, Philip T. Cagle et al. Journal of Thoracic Oncology
  5. Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation (1994)
    Esperanza B. Papadopoulos, Marc Ladanyi et al. New England Journal of Medicine
  6. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006)
    Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research
  7. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006)
    Gregory J. Riely, William Pao et al. Clinical Cancer Research
  8. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor (2010)
    James E. Butrynski, David R. D’Adamo et al. New England Journal of Medicine
  9. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation (2012)
    Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery
  10. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis (2009)
    Ronglai Shen, Adam B. Olshen et al. Bioinformatics
  11. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma (2011)
    Matthew J. Bott, Marie Brevet et al. Nature Genetics
  12. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes (2017)
    Catherine C. Coombs, Ahmet Zehir et al. Cell stem cell
  13. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations (2011)
    Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology
  14. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010)
    Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research
  15. Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers (2012)
    Snjezana Doğan, Ronglai Shen et al. Clinical Cancer Research
  16. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011)
    Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research
  17. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013)
    Justin F. Gainor, Anna M. Varghese et al. Clinical Cancer Research
  18. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping (2015)
    Paul K. Paik, Alexander Drilon et al. Cancer Discovery
  19. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls (2019)
    James P. Solomon, Irina Linkov et al. Modern Pathology
  20. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions (2017)
    Jaclyn F. Hechtman, Ryma Benayed et al. The American Journal of Surgical Pathology
  21. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial (2016)
    Alexander Drilon, Natasha Rekhtman et al. The Lancet Oncology
  22. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden (2019)
    Ryma Benayed, Michael Offin et al. Clinical Cancer Research
  23. Identifying patients with NTRK fusion cancer (2019)
    James P. Solomon, Ryma Benayed et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 38 from Science/Nature 136 standout
Sub-graph 1 of 18

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
2023 StandoutNature
10 intermediate papers

Works of Marc Ladanyi being referenced

WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis
2009
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
2006 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Marc Ladanyi 34881 23968 21682 611 55.8k
Robert J. Motzer 38543 19079 30079 921 57.3k
Razelle Kurzrock 12014 24289 20512 1.2k 58.6k
Matt van de Rijn 9590 18943 22854 250 49.3k
Cristina R. Antonescu 27923 14329 8674 543 42.6k
Mark A. Rubin 22807 10193 26319 545 48.4k
William L. Gerald 11903 11849 18572 239 35.4k
Carlos Cordon‐Cardo 10872 22560 40955 563 67.3k
Maria J. Merino 16984 7967 12076 584 36.6k
Jean‐Yves Blay 25741 18978 5361 1.2k 43.9k
George D. Demetri 23206 10951 6557 342 37.2k

All Works

Loading papers...

Rankless by CCL
2026